LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Nektar Therapeutics

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERNKTR
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / NKTR COVERAGE

What’s moving Nektar Therapeutics now

Current reporting with the operating signal separated from the noise.

01
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

The story matters when it changes Nektar Therapeutics’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Nektar Therapeutics Reports Vesting of 16,500 Stock Options for Chief R&D Officer Jonathan Zalevsky

Nektar Therapeutics Reports Vesting of 16,500 Stock Options for Chief R&D Officer Jonathan Zalevsky

Investors are testing whether Nektar Therapeutics’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
03
Nektar Therapeutics: This Stock Went Up 10x In The Last Year And It's Still Cheap

Nektar Therapeutics: This Stock Went Up 10x In The Last Year And It's Still Cheap

Investors are testing whether Nektar Therapeutics’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead

Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead

Investors are testing whether Nektar Therapeutics’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Nektar Therapeutics Is Up 150%: What’s Happening With NKTR Stock?

Nektar Therapeutics Is Up 150%: What’s Happening With NKTR Stock?

Investors are testing whether Nektar Therapeutics’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
Nektar Therapeutics's Earnings: A Preview

Nektar Therapeutics's Earnings: A Preview

Investors are testing whether Nektar Therapeutics’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest NKTR filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-08 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-07 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-13 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-05 · Period 2026-06-05SEC ↗8-KMaterial company eventFiled 2026-05-08 · Period 2026-05-08SEC ↗8-KMaterial company eventFiled 2026-05-07 · Period 2026-05-07SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-24 · Period 2026-06-04SEC ↗SCHEDULE 13GOfficial SEC filingFiled 2026-07-31SEC ↗
EARNINGS / QUARTERLY TRACKER

Nektar Therapeutics, quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.